Two data points published within weeks of each other frame the diamond trade's central tension going into the fourth quarter of 2026. The first, from a BriteCo report released September 25, shows lab-grown diamonds reached 51% of newly appraised engagement rings in the first half of 2026, up from 47% for full-year 2025. The second, from Rapaport, shows the 1-carat RAPI rose 0.5% in August, its first increase in 15 months. One measures share. The other measures price. Read together they describe a market splitting cleanly into two tracks.

The share story

Crossing the halfway mark is a threshold worth stating plainly: for the first time, more than half of newly appraised engagement rings carried a laboratory-grown center stone. The move from 47% to 51% in roughly eighteen months is not a fad curve flattening out. It is a category continuing to take share at the point of the most emotionally weighted purchase in the business.

The price gap explains the pull. BriteCo's 2025 figures put the median lab-grown diamond at $2,057 per carat against $8,428 per carat for natural. At the ring level the spread is starker still: a median natural engagement ring ran $12,961 while the median lab-grown ring came in at $4,557. And the wholesale floor keeps dropping. TheDiamondPrice.com pegged the fair market price of a 1-carat lab-grown at $670 as of September 19, 2026. When a consumer can put a visibly larger stone on the hand for a fraction of the outlay, the appraisal statistics were always going to move in one direction.

The price story

Against that share erosion, the natural market delivered its first constructive print in more than a year. The 1-carat RAPI rose 0.5% in August, the first increase in 15 months. Smaller categories moved more decisively: the 0.30-carat index jumped 2% and 0.50-carat goods advanced 2.5%. The 3-carat index slipped 0.4%, so the recovery is concentrated at the smaller sizes rather than uniform across the board.

That pattern is telling. Gains led by 0.30- and 0.50-carat goods point to retail restocking rather than investment buying, which is the healthier foundation for a turn. After 15 months of watching sellers chase the benchmark lower, a green print at the 1-carat mark changes the negotiating posture across the rough pipeline. It does not, by itself, reverse the share story above it. For the wider trade picture this week, the retail read is covered in the industry report.

Two tracks, one counter

The structural reading is that natural and lab-grown are decoupling into distinct products serving distinct buyers. Lab-grown is winning volume at the entry and mid tiers where price dominates the decision, its median per-carat price now roughly a quarter of natural's. Natural is stabilizing as a smaller, value-anchored category, with the August RAPI turn suggesting the price reset that ran through 2024 and 2025 has finally found a floor at the sizes retail actually sells.

De Beers has spent the year defending that floor on the rough side. Its first sight of 2026 totaled $450 million in rough diamond sales back in January, a baseline the miner has managed against ever since. The task on the counter is different but related: presenting the two products honestly to a consumer who now, more often than not, is choosing the grown stone. A 51% share is no longer the story of an insurgent. It is the story of a market where the laboratory stone is the default and natural is the considered alternative.

What to watch

The question for the fourth quarter is whether August's RAPI turn holds and broadens beyond the smaller sizes, or fades as a one-month blip the way earlier false starts did. If the September index confirms the 0.5% gain and retail holiday demand backs it, the natural trade will have its first two-sided market in more than a year. If it does not, the two tracks keep diverging, with lab-grown share climbing past 51% and natural leaning ever harder on scarcity as its argument. The lab-grown recovery on the natural side is set against the broader tape in the trade week wrap. The single number that matters most into the holiday: whether lab-grown's share keeps climbing above 51% or steadies there.